Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

The stock's fall snapped a four-day winning streak.

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Pfizer's stock declined over 50% due to reduced sales ... The remarkable improvement was driven by the strong performance of Pfizer's core portfolio, particularly its drugs that treat cancer ...

MphasiS's stock performance today reflects a positive shift, with a notable price increase. Investors and market participants ...

With the stock currently trading at Rs 641.90, Syngene International showcases a moderate uptrend in today's session, amidst ...

Read about why American Assets Trust & Alexandria Real Estate are top REIT stock picks for long-term dividends.